ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1547

Impact of Obesity on Drug Survival of Tofacitinib in Patients with Rheumatoid Arthritis: Analysis from the Turkbio Registry

Hakan Babaoglu1, Berna Goker1, Nevsun İnanç2, Merih Birlik3, Suleyman Serdar Koca4, Ayse Cefle5, Ediz Dalkiliç6, Abdurrahman Tufan1, Sema Yilmaz7, Soner Senel8, Servet Akar9, Nurullah Akkoc10, Fatos Onen3 and Ummugulsum Gazel11, 1Internal Medicine-Rheumatology, Gazi University Faculty of Medicine, Ankara, Turkey, 2Rheumatology, Marmara University faculty of Medicine, İstanbul, Turkey, 3Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, 4Rheumatology, Firat University Faculty of Medicine, Elazığ, Turkey, 5Rheumatology, Kocaeli University, Faculty of Medicine, Kocaeli, Turkey, 6Department of Internal Medicine, Division of Rheumatology, Uludağ University Faculty of Medicine, Bursa, Turkey, 7Department of Rheumatology, Selcuk University School of Medicine, Konya, Turkey, 8Rheumatology, Kayseri Erciyes University, Faculty of Medicine, Kayseri, Turkey, 9Department of Internal Medicine, Division of Rheumatology,, Izmir Katip Çelebi University Faculty of Medicine, Izmir, Turkey, 10Rheumatology, İzmir, Turkey, İzmir, Turkey, 11Rheumatology, Marmara University faculty of Medicine, Istanbul, Turkey

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: drug treatment, obesity, rheumatoid arthritis (RA) and tofacitinib

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, October 22, 2018

Session Title: Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Several previous reports suggest that obesity impairs the effectiveness and drug survival of anti-TNF-α agents in rheumatoid arthritis (RA). The aim of the study was to analyze the impact of obesity on drug survival of tofacitinib in patient with RA, based on their baseline body mass index (BMI).

Methods:

Data on patient characteristics, demographics, diagnosis, disease duration, treatment and outcomes have been collected since 2011 in Turkish Biologic (TURKBIO) Registry. By the end of May 2018, 140 RA patients received tofacitinib and were included. Demographic and clinical data including age, sex, disease type, disease duration and previous or current treatment with DMARDs and biological drug durations are stored in the database. Kaplan-Meier survival analysis was performed to estimate the drug survival.

Results:

All patients received tofacitinib 5 mg BID. Patients were grouped according to BMI. Forty-eight were obese (BMI >30), 92 were non-obese patients.  Obese patients were found to be older, had more DM and HT compared to non-obese patients as expected (Table 1). Gender distribution, disease duration, serologic positivity, previous or current treatment with DMARDs, previous TNH inhibitor or non-TNF biological drug use, concomitant prednisolone use and mean clinical and laboratory parameters through the observation period did not differ between groups. Tofacitinib treatment was ongoing in 59.8% in non-obese and 70.8% in obese patients. Median drug survival duration was 10 months in non-obese patients and 24 months in obese ones (p=0.1). Estimated drug survival rates for tofacitinib were not statistically significantly different between groups (Figure 1).

Conclusion:

 Real life experience from this nationwide TURKBIO registry suggests obesity does not adversely affect drug survival of tofacitinib in patients with RA. Further studies are needed to study impact of obesity on its clinical efficacy.


Disclosure: H. Babaoglu, None; B. Goker, None; N. İnanç, None; M. Birlik, None; S. S. Koca, None; A. Cefle, None; E. Dalkiliç, None; A. Tufan, None; S. Yilmaz, None; S. Senel, None; S. Akar, None; N. Akkoc, None; F. Onen, None; U. Gazel, None.

To cite this abstract in AMA style:

Babaoglu H, Goker B, İnanç N, Birlik M, Koca SS, Cefle A, Dalkiliç E, Tufan A, Yilmaz S, Senel S, Akar S, Akkoc N, Onen F, Gazel U. Impact of Obesity on Drug Survival of Tofacitinib in Patients with Rheumatoid Arthritis: Analysis from the Turkbio Registry [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/impact-of-obesity-on-drug-survival-of-tofacitinib-in-patients-with-rheumatoid-arthritis-analysis-from-the-turkbio-registry/. Accessed May 25, 2022.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-obesity-on-drug-survival-of-tofacitinib-in-patients-with-rheumatoid-arthritis-analysis-from-the-turkbio-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.